Breaking News
Get 50% Off 0
💎 Bargain Hunter: Undervalued stocks with massive upside potential
Get the list
Close

Y mAbs Therapeutics (YMAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Y mAbs Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.52 0.00    0.00%
06/08 - Closed. Currency in USD
After Hours
8.51
-0.01
-0.12%
23:33:02 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,547,635
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 8.50 - 8.52
Y mAbs Therapeutics 8.52 0.00 0.00%

Y mAbs Therapeutics Company Profile

 
Get an in-depth profile of Y mAbs Therapeutics, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

104

Equity Type

ORD

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Contact Information

Address 202 Carnegie Center Suite 301
Princeton, 08540
United States
Phone 646 885 8505
Fax -

Top Executives

Name Age Since Title
Ashutosh Tyagi 48 2017 Independent Director
James Irvin Healy 60 2017 Independent Chairman of the Board
David N. Gill 70 2017 Independent Director
Johan Ernst Wedell-Wedellsborg 55 2015 Independent Director
Thomas Gad 55 2015 Founder, Chief Business Officer & Vice Chairman
Laura Jean Hamill 60 2020 Independent Director
Michael Rossi 54 2023 CEO, President & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

YMAB Comments

Write your thoughts about Y mAbs Therapeutics
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email